Cullinan Therapeutics, Inc. (CGEM) Cash Flow Statement
Cullinan Therapeutics, Inc. (CGEM) generated -$159.3M of operating cash flow over the twelve months to 2026-06-30, spent $49000 on capital expenditure and had free cash flow of -$159.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CGEMCullinan Therapeutics, Inc.Follow CGEM — free
—
Price chart with a free account
- Market cap
- 924.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -43.4 | -126.7 | -134.3 | -145.3 | -175.8 | -159.3 | |
| Capital expenditure | 0.0 | 1.1 | 0.2 | 0.0 | 0.0 | -0.0 | |
| Free cash flow | -43.4 | -127.8 | -134.5 | -145.3 | -175.8 | -159.3 | |
| Stock-based compensation | 24.4 | 28.0 | 30.4 | 37.8 | 36.0 | — |
USD millions · SEC XBRL
Cullinan Therapeutics, Inc. — questions
- What is Cullinan Therapeutics, Inc.'s operating cash flow?
- -$159.3M over the twelve months to 2026-06-30.
- How much does Cullinan Therapeutics, Inc. spend on capital expenditure?
- $49000 over the twelve months to 2026-06-30.
- What is Cullinan Therapeutics, Inc.'s free cash flow?
- -$159.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Cullinan Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.